Teixeira Patrícia V, Fernandes Eduarda, Soares Telma B, Adega Filomena, Lopes Carla M, Lúcio Marlene
CF-UM-UP-Centro de Física das Universidades do Minho e Porto, Departamento de Física da Universidade do Minho, 4710-057 Braga, Portugal.
CytoGenomics Lab, Department of Genetics and Biotechnology, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal.
Pharmaceutics. 2023 Apr 21;15(4):1317. doi: 10.3390/pharmaceutics15041317.
Cancer is one of the leading causes of death, and latest predictions indicate that cancer- related deaths will increase over the next few decades. Despite significant advances in conventional therapies, treatments remain far from ideal due to limitations such as lack of selectivity, non-specific distribution, and multidrug resistance. Current research is focusing on the development of several strategies to improve the efficiency of chemotherapeutic agents and, as a result, overcome the challenges associated with conventional therapies. In this regard, combined therapy with natural compounds and other therapeutic agents, such as chemotherapeutics or nucleic acids, has recently emerged as a new strategy for tackling the drawbacks of conventional therapies. Taking this strategy into consideration, the co-delivery of the above-mentioned agents in lipid-based nanocarriers provides some advantages by improving the potential of the therapeutic agents carried. In this review, we present an analysis of the synergistic anticancer outcomes resulting from the combination of natural compounds and chemotherapeutics or nucleic acids. We also emphasize the importance of these co-delivery strategies when reducing multidrug resistance and adverse toxic effects. Furthermore, the review delves into the challenges and opportunities surrounding the application of these co-delivery strategies towards tangible clinical translation for cancer treatment.
癌症是主要死因之一，最新预测表明，未来几十年与癌症相关的死亡人数将会增加。尽管传统疗法取得了重大进展，但由于缺乏选择性、非特异性分布和多药耐药性等局限性，治疗效果仍远不尽如人意。当前的研究集中在开发多种策略以提高化疗药物的效率，从而克服传统疗法所带来的挑战。在这方面，天然化合物与其他治疗剂（如化疗药物或核酸）的联合治疗最近已成为应对传统疗法缺点的一种新策略。考虑到这一策略，将上述药物共同负载于脂质纳米载体中，通过提高所载治疗剂的潜力而具有一些优势。在本综述中，我们分析了天然化合物与化疗药物或核酸联合使用所产生的协同抗癌效果。我们还强调了这些共同递送策略在降低多药耐药性和不良毒性作用方面的重要性。此外，本综述深入探讨了这些共同递送策略在实现癌症治疗切实临床转化应用方面所面临的挑战和机遇。
